Digital Pathology Market by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) - Global Forecast to 2030
디지털 병리 검사 시장 규모는 유형별로 스캐너, 스토리지 시스템, 소프트웨어의 세 가지로 구분됩니다.
디지털 퍼솔로지 워크플로우에서 이러한 장비의 중요성을 감안할 때 2024년에는 스캐너가 제품 범주에서 가장 큰 점유율을 차지하고 있습니다. 의사가 물리적인 장소를 불문하고 증례를 평가할 수 있게 하는 것으로, 병리학 서비스의 접근성과 효율성을 향상시키기 위해서 가장 중요하고, 그 때문에 스캐너 수요가 높아지고 있습니다. 스캐닝 속도의 향상이나 고해상도의 이미징 등, 스캐너 기술의 진보는 워크 플로우 증가, 진단 정밀도의 향상, 검사실 및 의료시설의 투자가치 향상을 가져옵니다.
| 조사 범위 |
| 조사 대상 연도 |
2024-2030년 |
| 기준연도 |
2024년 |
| 예측 기간 |
2024-2030년 |
| 검토 단위 |
금액(10억 달러) |
| 부문 |
제품별, 유형별, 용도별, 최종 사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
암, 심혈관 질환, 감염증 등 적시에 정확한 진단 결과를 필요로 하는 복잡하고 만성적인 질환의 세계 부담이 증가하고 있는 것이 주된 이유입니다.
일반적으로 현미경의 접안 렌즈 아래에서 수행되는 디지털 병리 검사, 검사, 진단은 고해상도 이미지 생성, 자동화된 분석 제공, 이미지 저장, 클라우드 스토리지, 원격 병리학 슬라이드 공유 서비스 제공 등 많은 면에서 유리합니다.
게다가 디지털 병리 검사는 인공지능(AI), 머신러닝(ML), 딥러닝 영상 인식 등의 최신 기술을 통합하기 위해 급속히 채용되어 진화하고 있습니다. 이것은 모두, 진단 정밀도의 향상, 소요 시간의 단축, 나아가 미묘한 조직학적 패턴의 인식에 도움이 되어, 디지털 병리 검사를 세계의 검사실이나 병원에서
북미는 성숙한 헬스케어 시스템과 헬스케어 기술 개척을 위한 대규모 재정 투자로 2024년 디지털 병리 검사 시장을 선도했습니다. 신속한 검토 및 승인 프로세스를 지원합니다. 이는 의료 서비스 제공업체의 의식 증가와 고급 진단 솔루션에 대한 수요가 증가함에 따라이 지역 전체에서 디지털 병리 검사의 강력한 보급을 뒷받침합니다.
본 보고서에서는 세계의 디지털 병리 검사 시장에 대해 조사했으며, 제품별, 유형별, 용도별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
- 소개
- 시장 역학
- 업계 동향
- 기술 분석
- 가격 분석
- 밸류체인 분석
- 생태계 분석
- Porter's Five Forces 분석
- HS코드
- 규제 상황
- 특허 분석
- 사례 연구 분석
- 2025-2026년의 주된 회의와 이벤트
- 주요 이해관계자와 구매 기준
- 최종 사용자 분석
- 비즈니스 모델 분석
- 투자 및 자금조달 시나리오
- AI가 디지털 병리 검사 시장에 미치는 영향
- 미국 관세가 디지털 병리 검사 시장에 미치는 영향
- 가격 영향 분석
- 국가/지역에 미치는 영향
제6장 디지털 병리 검사 시장(제품별)
- 소개
- 스캐너
- 소프트웨어
- 소프트웨어(도입 모델별)
- 스토리지 시스템
제7장 디지털 병리 검사 시장(유형별)
제8장 디지털 병리 검사 시장(용도별)
제9장 디지털 병리 검사 시장(최종 사용자별)
- 소개
- 제약 및 바이오테크놀러지 기업
- 병원 및 검사 기관
- 학술연구기관
- 진단실험실
- 수의학 연구소
제10장 디지털 병리 검사 시장(지역별)
- 소개
- 북미
- 유럽
- 유럽 : 거시경제 전망
- 독일
- 영국
- 스웨덴
- 프랑스
- 스페인
- 이탈리아
- 기타
- 아시아태평양
- 아시아태평양 : 거시경제 전망
- 중국
- 일본
- 인도
- 기타
- 라틴아메리카
- 라틴아메리카 : 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
- 시장 성장을 지원하는 헬스케어 인프라 개선
- 중동 및 아프리카의 거시경제 전망
- GCC 국가
- 기타
제11장 경쟁 구도
- 개요
- 주요 진입기업의 전략/강점
- 수익 분석
- 시장 점유율 분석
- 기업평가 매트릭스 : 주요 진입기업, 2023년
- 기업평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업평가와 재무지표
- 브랜드/소프트웨어 비교 분석
- 경쟁 시나리오
제12장 기업 프로파일
- 주요 진출기업
- DANAHER CORPORATION
- HOFFMANN-LA ROCHE LTD.
- SECTRA AB
- HAMAMATSU PHOTONICS KK
- KONINKLIJKE PHILIPS NV
- AKOYA BIOSCIENCES, INC.
- FUJIFILM HOLDINGS CORPORATION
- HOLOGIC, INC.
- 3DHISTECH LTD.
- APOLLO ENTERPRISE IMAGING CORP.
- XIFIN, INC.
- HURON DIGITAL PATHOLOGY
- INDICA LABS
- OPTRASCAN, INC.
- GLENCOE SOFTWARE, INC.
- AIFORIA TECHNOLOGIES OY
- PAIGE AI, INC.
- PROSCIA, INC.
- 기타 기업
- QUEST DIAGNOSTICS
- KONFOONG BIOTECH INTERNATIONAL CO., LTD.
- MIKROSCAN TECHNOLOGIES, INC.
- MOTIC DIGITAL PATHOLOGY
- KANTERON SYSTEMS
- MORPHLE LABS INC.
- EW HEALTHCARE PARTNERS
제13장 부록
JHS
The market for digital pathology is segmented into three categories based on type: scanners, storage systems, and software. Given the significance of these devices in the digital pathology workflow, the scanners segment accounted for the largest share of the product category in 2024. Scanners are critical in enabling pathologists to view and analyze tissue samples on computer screens, as scanners convert physical glass slides to high-resolution digital images. The development of diagnostic remote access is paramount for improved accessibility and efficiency of pathology services by allowing pathologists to evaluate cases from any physical location, hence, the demand for scanners. The advancements in scanner technology, such as improved scanning rates and greater resolution imaging, have led to increased workflow, improved diagnostic accuracy, and value for investment for laboratories or medical facilities.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | Product, Type, Application, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
By type, the human pathology segment is expected to hold the largest share during the forecast period.
The human pathology segment is expected to occupy the largest share of the digital pathology market throughout the forecast period largely due to the rising global burden of complex and chronic diseases, including cancer, cardiovascular diseases, and infections, which demand timely and accurate diagnostic outcomes.
Digital pathology, examination, and diagnosis, typically performed under the eyepiece of a microscope, are advantageous in many aspects, such as producing high-resolution images, providing automated analytics, allowing for image storage, cloud storage, and telepathology slide-sharing services. Equally important is the unparalleled advantage of being able to provide remote consultation that may involve co-consultation and coordination at various sites and second opinions from specialists.
Furthermore, digital pathology is quickly being adopted and evolving to integrate the newest technologies such as artificial intelligence (AI), machine learning (ML), deep learning image recognition, which are all improving diagnostic accuracy, decreasing turnaround time, and even aiding in recognizing subtle histological patterns, which makes digital pathology a foundational element of practice in laboratories and hospitals around the world.
North America is expected to lead the global digital pathology market during the forecast period.
North America led the digital pathology market in 2024 due to a mature healthcare system and large financial investments toward developing healthcare technology. The regulatory environment in North America-especially in the US and Canada-supports a relatively faster review and approval process for emerging digital pathology technologies. This, combined with growing awareness among healthcare providers and rising demand for advanced diagnostic solutions, has driven strong adoption of digital pathology across the region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
- By Designation: C-level (35%), Director-level (25%), and Others (40%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East & Africa (5%)
List of Companies Profiled in the Report
Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain)
Research Coverage
This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (Growing adoption of AI-enabled digital pathology, rising burden of cancer, diabetes, and chronic diseases, expansion of digital pathology in drug discovery and biomarker validation, Cancer screening programs in emerging markets), restraints (High initial capital costs, Data interoperability issues with existing lab systems, regulatory and reimbursement uncertainty), opportunities (Affordable scanner development for low-resource settings, growing preference for personalized medicine, government-backed digitization in emerging economies) challenges (Shortage of skilled pathologists and technicians, algorithm validation issues, data security and patient privacy concerns), are contributing the growth of the digital pathology market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market
- Market Development: Comprehensive information about lucrative markets and analysis of the authentication and brand protection market across varied regions
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the digital pathology market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED
- 1.3.3 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH APPROACH
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 Key industry insights
- 2.2 RESEARCH METHODOLOGY DESIGN
- 2.3 MARKET SIZE ESTIMATION
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 MARKET ASSUMPTIONS
- 2.6.1 OVERALL STUDY ASSUMPTIONS
- 2.7 RISK ASSESSMENT
- 2.8 RESEARCH LIMITATIONS
- 2.8.1 METHODOLOGY-RELATED LIMITATIONS
- 2.8.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
- 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER AND COUNTRY (2024)
- 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 DIGITAL PATHOLOGY MARKET: REGIONAL MIX
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 AI-enabled digital pathology improving lab throughput
- 5.2.1.2 Rising burden of cancer, diabetes, and cardiovascular diseases
- 5.2.1.3 Expansion of digital pathology in drug discovery and biomarker validation
- 5.2.1.4 National cancer screening programs in emerging markets
- 5.2.2 RESTRAINTS
- 5.2.2.1 High initial capital cost of digital pathology systems
- 5.2.2.2 Data interoperability issues with existing lab systems
- 5.2.2.3 Regulatory and reimbursement uncertainty
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Affordable scanner development for low-resource settings
- 5.2.3.2 Personalized medicine driving precision diagnostics
- 5.2.3.3 Government-backed digitalization in emerging economies
- 5.2.4 CHALLENGES
- 5.2.4.1 Shortage of skilled pathologists and technicians
- 5.2.4.2 Algorithm validation and trust in AI-based diagnostics
- 5.2.4.3 Data security and privacy concerns
- 5.3 INDUSTRY TRENDS
- 5.3.1 AI-POWERED DIAGNOSTICS GO MAINSTREAM
- 5.3.2 CLOUD-BASED PLATFORMS AND REMOTE ACCESS BECOME CRITICAL ENABLERS
- 5.4 TECHNOLOGY ANALYSIS
- 5.4.1 CLOUD STORAGE & ARCHIVING
- 5.4.2 WHOLE SLIDE IMAGING (WSI) SCANNERS
- 5.4.3 IMAGE MANAGEMENT SYSTEMS
- 5.4.4 ADJACENT TECHNOLOGIES
- 5.4.4.1 Genomic sequencing
- 5.4.4.2 Artificial Intelligence and Machine Learning
- 5.4.5 COMPLEMENTARY TECHNOLOGIES
- 5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
- 5.5.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 PORTER'S FIVE FORCES ANALYSIS
- 5.8.1 THREAT OF NEW ENTRANTS
- 5.8.2 THREAT OF SUBSTITUTES
- 5.8.3 BARGAINING POWER OF SUPPLIERS
- 5.8.4 BARGAINING POWER OF BUYERS
- 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.9 HS CODES
- 5.10 REGULATORY LANDSCAPE
- 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10.2 REGULATORY ANALYSIS
- 5.10.2.1 North America
- 5.10.2.1.1 US
- 5.10.2.1.2 Canada
- 5.10.2.2 Europe
- 5.10.2.3 Asia Pacific
- 5.10.2.3.1 Japan
- 5.10.2.3.2 China
- 5.10.2.3.3 India
- 5.11 PATENT ANALYSIS
- 5.11.1 PATENT PUBLICATION TRENDS
- 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS
- 5.11.3 MAJOR PATENTS
- 5.12 CASE STUDY ANALYSIS
- 5.13 KEY CONFERENCES & EVENTS, 2025-2026
- 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA
- 5.14.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.15 END-USER ANALYSIS
- 5.15.1 UNMET NEEDS
- 5.15.2 END-USER EXPECTATIONS
- 5.16 BUSINESS MODEL ANALYSIS
- 5.17 INVESTMENT & FUNDING SCENARIO
- 5.18 IMPACT OF AI ON DIGITAL PATHOLOGY MARKET
- 5.19 IMPACT OF US TARIFF ON DIGITAL PATHOLOGY MARKET
- 5.19.1 INTRODUCTION
- 5.19.2 KEY TARIFF RATES
- 5.20 PRICE IMPACT ANALYSIS
- 5.21 IMPACT ON COUNTRY/REGION
- 5.21.1 US
- 5.21.2 EUROPE
- 5.21.3 ASIA PACIFIC
- 5.21.4 IMPACT ON END-USE INDUSTRIES
6 DIGITAL PATHOLOGY MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 SCANNERS
- 6.2.1 BRIGHTFIELD SCANNERS
- 6.2.1.1 Cost-efficient features to boost demand
- 6.2.2 FLUORESCENCE SCANNERS
- 6.2.2.1 Ability to detect cellular structures and biomarkers to fuel uptake
- 6.2.3 OTHER SCANNERS
- 6.3 SOFTWARE
- 6.3.1 INTEGRATED SOFTWARE
- 6.3.1.1 Single & effective suite for multiple applications to propel market
- 6.3.2 STANDALONE SOFTWARE
- 6.3.2.1 Information management software
- 6.3.2.1.1 Management of image repositories to fuel uptake
- 6.3.2.2 Image analysis software
- 6.3.2.2.1 Ability to automate quantitative evaluation to support market growth
- 6.4 SOFTWARE, BY DEPLOYMENT MODEL
- 6.4.1 CLOUD-BASED MODEL
- 6.4.1.1 Facilitation of collaboration on a single platform to drive market
- 6.4.2 ON-PREMISE MODEL
- 6.4.2.1 High data security and integration with HCIT solutions to fuel uptake
- 6.4.3 HYBRID MODEL
- 6.4.3.1 Combined flexibility to support market growth
- 6.5 STORAGE SYSTEMS
- 6.5.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET
7 DIGITAL PATHOLOGY MARKET, BY TYPE
- 7.1 INTRODUCTION
- 7.2 HUMAN PATHOLOGY
- 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET
- 7.3 VETERINARY PATHOLOGY
- 7.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH
8 DIGITAL PATHOLOGY MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 DRUG DISCOVERY
- 8.2.1 INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET
- 8.3 DISEASE DIAGNOSIS
- 8.3.1 INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND
- 8.4 TRAINING & EDUCATION
- 8.4.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH
9 DIGITAL PATHOLOGY MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET
- 9.3 HOSPITALS & REFERENCE LABORATORIES
- 9.3.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
- 9.4 ACADEMIC & RESEARCH INSTITUTES
- 9.4.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH
- 9.5 DIAGNOSTICS LABORATORIES
- 9.5.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH
- 9.6 VETERINARY LABORATORIES
- 9.6.1 TECHNOLOGICAL ADVANCEMENTS, PARTICULARLY IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE, SUPPORT MARKET GROWTH
10 DIGITAL PATHOLOGY MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 10.2.2 US
- 10.2.2.1 Favorable reimbursements for diagnostics to drive market
- 10.2.3 CANADA
- 10.2.3.1 Growing awareness on early cancer detection & diagnosis to drive market
- 10.3 EUROPE
- 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 10.3.2 GERMANY
- 10.3.2.1 High healthcare expenditure and supportive research initiatives to drive market
- 10.3.3 UK
- 10.3.3.1 Government funding investments for pathology services to fuel market
- 10.3.4 SWEDEN
- 10.3.4.1 Increasing prevalence of chronic diseases to support market growth
- 10.3.5 FRANCE
- 10.3.5.1 Increasing government funding and favorable insurance system to drive adoption
- 10.3.6 SPAIN
- 10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand
- 10.3.7 ITALY
- 10.3.7.1 Integration of AI & ML to support market growth
- 10.3.8 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 10.4.2 CHINA
- 10.4.2.1 Increasing establishment of hospitals and reference laboratories to drive market
- 10.4.3 JAPAN
- 10.4.3.1 Advanced healthcare infrastructure to support market growth
- 10.4.4 INDIA
- 10.4.4.1 Growth in pharmaceutical industry to propel market
- 10.4.5 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 10.5.2 BRAZIL
- 10.5.2.1 High adoption of POC testing to drive market
- 10.5.3 MEXICO
- 10.5.3.1 Growth in companion diagnostics to fuel uptake
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST & AFRICA
- 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
- 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 10.6.3 GCC COUNTRIES
- 10.6.4 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
- 11.3 REVENUE ANALYSIS
- 11.4 MARKET SHARE ANALYSIS
- 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 11.5.5.1 Company footprint
- 11.5.5.2 Product footprint
- 11.5.5.3 Application footprint
- 11.5.5.4 End-user footprint
- 11.5.5.5 Region footprint
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 11.7 COMPANY VALUATION AND FINANCIAL METRICS
- 11.8 BRAND/SOFTWARE COMPARATIVE ANALYSIS
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
- 11.9.2 DEALS
- 11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
- 12.1 KEY COMPANIES
- 12.1.1 DANAHER CORPORATION
- 12.1.1.1 Business overview
- 12.1.1.2 Products offered
- 12.1.1.3 Recent developments
- 12.1.1.4 MnM view
- 12.1.1.4.1 Key strengths
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 HOFFMANN-LA ROCHE LTD.
- 12.1.2.1 Business overview
- 12.1.2.2 Products offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Product launches & approvals
- 12.1.2.3.2 Deals
- 12.1.2.4 MnM view
- 12.1.2.4.1 Key strengths
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 SECTRA AB
- 12.1.3.1 Business overview
- 12.1.3.2 Products offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Deals
- 12.1.3.3.2 Other developments
- 12.1.3.4 MnM view
- 12.1.3.4.1 Key strengths
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 HAMAMATSU PHOTONICS K.K.
- 12.1.4.1 Business overview
- 12.1.4.2 Products offered
- 12.1.4.3 Recent developments
- 12.1.4.3.1 Product approvals
- 12.1.4.3.2 Deals
- 12.1.4.4 MnM view
- 12.1.4.4.1 Key strengths
- 12.1.4.4.2 Strategic choices
- 12.1.4.4.3 Weaknesses and competitive threats
- 12.1.5 KONINKLIJKE PHILIPS N.V.
- 12.1.5.1 Business overview
- 12.1.5.2 Products offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Product launches & approvals
- 12.1.5.3.2 Deals
- 12.1.5.4 MnM view
- 12.1.5.4.1 Key strengths
- 12.1.5.4.2 Strategic choices
- 12.1.5.4.3 Weaknesses and competitive threats
- 12.1.6 AKOYA BIOSCIENCES, INC.
- 12.1.6.1 Business overview
- 12.1.6.2 Products offered
- 12.1.6.3 Recent developments
- 12.1.6.3.1 Product launches & approvals
- 12.1.7 FUJIFILM HOLDINGS CORPORATION
- 12.1.7.1 Business overview
- 12.1.7.2 Products offered
- 12.1.7.3 Recent developments
- 12.1.8 HOLOGIC, INC.
- 12.1.8.1 Business overview
- 12.1.8.2 Products offered
- 12.1.8.3 Recent developments
- 12.1.8.3.1 Product approvals
- 12.1.9 3DHISTECH LTD.
- 12.1.9.1 Business overview
- 12.1.9.2 Products offered
- 12.1.9.3 Recent developments
- 12.1.9.3.1 Product launches & enhancements
- 12.1.9.3.2 Other developments
- 12.1.10 APOLLO ENTERPRISE IMAGING CORP.
- 12.1.10.1 Business overview
- 12.1.10.2 Products offered
- 12.1.10.3 Recent developments
- 12.1.10.3.1 Product enhancements
- 12.1.10.3.2 Deals
- 12.1.11 XIFIN, INC.
- 12.1.11.1 Business overview
- 12.1.11.2 Products offered
- 12.1.11.3 Recent developments
- 12.1.11.3.1 Product launches
- 12.1.11.3.2 Deals
- 12.1.12 HURON DIGITAL PATHOLOGY
- 12.1.12.1 Business overview
- 12.1.12.2 Products offered
- 12.1.13 INDICA LABS
- 12.1.13.1 Business overview
- 12.1.13.2 Products offered
- 12.1.13.3 Recent developments
- 12.1.13.3.1 Product launches & approvals
- 12.1.13.3.2 Deals
- 12.1.14 OPTRASCAN, INC.
- 12.1.14.1 Business overview
- 12.1.14.2 Products offered
- 12.1.14.3 Recent developments
- 12.1.14.3.1 Product launches & approvals
- 12.1.14.3.2 Deals
- 12.1.15 GLENCOE SOFTWARE, INC.
- 12.1.15.1 Business overview
- 12.1.15.2 Products offered
- 12.1.15.3 Recent developments
- 12.1.15.3.1 Product enhancements
- 12.1.16 AIFORIA TECHNOLOGIES OY
- 12.1.16.1 Business overview
- 12.1.16.2 Products offered
- 12.1.16.3 Recent developments
- 12.1.17 PAIGE AI, INC.
- 12.1.17.1 Business overview
- 12.1.17.2 Products offered
- 12.1.17.3 Recent developments
- 12.1.17.3.1 Product launches & enhancements
- 12.1.17.3.2 Deals
- 12.1.18 PROSCIA, INC.
- 12.1.18.1 Business overview
- 12.1.18.2 Products offered
- 12.1.18.3 Recent developments
- 12.1.18.3.1 Product enhancements & approvals
- 12.1.18.3.2 Deals
- 12.2 OTHER PLAYERS
- 12.2.1 QUEST DIAGNOSTICS
- 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
- 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
- 12.2.4 MOTIC DIGITAL PATHOLOGY
- 12.2.5 KANTERON SYSTEMS
- 12.2.6 MORPHLE LABS INC.
- 12.2.7 EW HEALTHCARE PARTNERS
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
